ArticleFrontiers in neurology2026
Esculentoside A mitigates oxidative stress and neuronal apoptosis in spinal cord injury by modulating the Nrf2/HO-1 pathway.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Spinal cord injury (SCI) is a profoundly disabling condition affecting the central nervous system. Neuronal apoptosis constitutes a critical pathological event leading to neurological dysfunctions, which is further exacerbated by oxidative stress following SCI. Esculentoside A (EsA), a bioactive saponin isolated from Phytolaca esculenta, exhibits neuroprotective potential in our preliminary studies. However, whether EsA attenuates oxidative stress and neuronal apoptosis in SCI remains unclear. Purpose: The current study aimed to investigate the protective potential of EsA against oxidative stress and neuronal apoptosis following SCI, and to elucidate the associated molecular mechanisms. Methods: SCI was modeled in rats via contusion using the PSI-IH 0400 Striker impactor, and rats were treated intraperitoneally with 10 mg/kg EsA once daily. The Basso, Beattie, and Bresnahan (BBB) scale, grid walk analysis, and footprint test were adopted to evaluate motor function dynamically. Histopathological alterations in spinal cord tissue were examined by Hematoxylin-eosin (HE), Luxol Fast Blue (LFB), and Nissl staining. Oxidative stress markers, including hydrogen peroxide (H Results: EsA significantly improved motor function and reduced histopathological damage in SCI rats. This neuroprotective effect was accompanied by a significant improvement in oxidative stress biomarkers and neuronal apoptosis in the injured spinal cord, coinciding with activation of the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) pathway. Conclusions: In conclusion, EsA exerts a neuroprotective effect against SCI by modulating oxidative stress and neuronal apoptosis partially through activation of the Nrf2/HO-1 pathway, indicating its promise as a therapeutic agent for SCI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.